Alpha Tau Medical Ltd (DRTSW)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

- Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

- Joint partnership leverages Alpha Tau’s highly potent, localized alpha-radiation technology and Tolmar’s...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local...

Alpha Tau to Participate in May Investor Conferences

JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

- Interim results from the first three brain cancer patients treated; two of whom demonstrated complete...